Sibylla Biotech applies its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI‑FIT) approach to design small-molecule Folding Interfering Degraders (FIDs) that bind folding intermediates to induce protein degradation. The company's lead candidate targets Cyclin D1, a protein amplified and overexpressed in multiple cancers and currently considered undruggable in its native state. Proceeds from the Series A will be used to advance its proprietary pipeline through preclinical evaluation and to expand its protein folding simulation technology platform. Sibylla intends to exploit the simulation platform to build out additional therapeutic programs across a broad range of indications. The company was established as a spin‑off from the Italian National Institute for Nuclear Physics, the University of Trento, and the University of Perugia, with initial support from the Telethon Foundation and seed funding from Vertis SGR. Sibylla is based in Verona, Italy.

Total raised

$23M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2022